Abstract:Recently, we and others reported that aged-tau knockout mice exhibit behavioural deficits, arguing for a role of functional tau protein in brain health. We also showed that these mice exhibit iron-dependent neurodegeneration and clioquinol (CQ), a drug that binds to iron, prevented the development of symptoms in tau KO mice. However, prospective treatments for neurodegenerative disorders will need to confer benefit to symptomatic patients. Here, CQ was given to symptomatic 12-months old tau KO mice to test whether this treatment was effective. Tau knockout mice (tau KO) and background C57BL6/SV129 control mice (WT), at 12 months of age, were treated with CQ chow (30mg/kg body weight /day) for 5.5 months. We monitored the mice by pole test and rotarod every three weeks during treatment period, and terminated this study when the mice were 17-months of age. Y maze tests were performed before the mice being euthanized for biochemical studies. Tyrosine hydroxylase staining was used for stereological estimation of nigral neurons. Dopamine was measured by HPLC. Before treatment commenced, tau KO mice exhibited cognitive loss (y-maze) and parkinsonism (rotarod, pole test), as previously reported. Over the course of the study, CQ treatment reversed the motor and cognitive impairment as evidenced by improvement in the Pole test (P<0.001) and Rotarod test (P=0.008) and y-maze (P=0.038). Restoration of behavioral disability reflected preservation of neuroanatomical features including enlargement of cortical thickness (P=0.026) and striatal enlargement (P=0.001) and reduction of the lateral ventricular area (P<0.001) at the conclusion of the study. These benefits conferred by CQ treatment could be attributed to reduction in iron load in the brain since treatment with CQ for 5.5 months had decreased iron in the brain (P=0.003 for hippocampus, and P=0.007 for SN) but not liver. Copper and zinc levels were unaffected. Here we report that iron chelation by CQ rescued several neurodegenerative phenotypes of aged tau KO mice, further supporting our hypothesis that tau plays a crucial role in age-related diseases. Importantly, these benefits were conferred to mice that began treatment after symptom manifestation, highlighting the potential for iron chelation approaches as disease modifying therapeutics for neurodegenerative diseases.

Clioquinol rescues Parkinsonism and dementia phenotypes of the tau knockout mouse.

Rescue of Behavioral and neurodegenerative phenotypes in symptomatic tau KO mice: Therapeutic implications for neurodegenerative diseases

Clioquinol improves motor and non-motor deficits in MPTP-induced monkey model of Parkinson’s disease through AKT/mTOR pathway

Motor and Cognitive Deficits in Aged Tau Knockout Mice in Two Background Strains

Beneficial effects of tri-lithium pyrroloquinoline quinonein on behaviors and pathology in a mouse model of Alzheimer’s disease

Tau-mediated Iron Export Prevents Ferroptotic Damage after Ischemic Stroke

Altered Brain Iron Depositions from Aging to Parkinson's Disease and Alzheimer's Disease: A Quantitative Susceptibility Mapping Study

A New Chiral Pyrrolyl Alpha-Nitronyl Nitroxide Radical Attenuates Beta-Amyloid Deposition And Rescues Memory Deficits In A Mouse Model Of Alzheimer Disease

Altered brain iron depositions from aging to Parkinson's disease and Alzheimer's disease: A quantitative susceptibility mapping study.

Senolytic therapy preserves blood-brain barrier integrity and promotes microglia homeostasis in a tauopathy model

Deferoxamine inhibits iron induced hippocampal tau phosphorylation in the Alzheimer transgenic mouse brain.

Cerebroprotein hydrolysate-I ameliorates cognitive dysfunction in APP/PS1 mice by inhibiting ferroptosis via the p53/SAT1/ALOX15 signalling pathway

Loss of Tau Induces Age-Dependent Anaemia with Reduced Longevity in Mice

O4‐08‐03: Loss of Tau Induces Age‐dependent Neurodegeneration

Resveratrol Rescues Tau-Induced Cognitive Deficits and Neuropathology in a Mouse Model of Tauopathy

Iron chelation by oral deferoxamine treatment decreased brain iron and iron signaling proteins

Clozapine-N-oxide protects dopaminergic neurons against rotenone-induced neurotoxicity by preventing ferritinophagy-mediated ferroptosis

Quercetagitrin Inhibits Tau Accumulation and Reverses Neuroinflammation and Cognitive Deficits in P301S-Tau Transgenic Mice

Ceruloplasmin, a Potential Therapeutic Agent for Alzheimer's Disease.

5-HT4 receptor agonists treatment reduces tau pathology and behavioral deficit in the PS19 mouse model of tauopathy

8-weeks aerobic exercise ameliorates cognitive deficit and mitigates ferroptosis triggered by iron overload in the prefrontal cortex of APP Swe/ PSEN 1dE9 mice through Xc-/GPx4 pathway